Terns Pharmaceuticals, Inc. (TERN) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 104 transactions totaling $102.9M, demonstrating a bullish sentiment with $76.6M in net insider flow. The most recent transaction on Feb 1, 2026 involved a transaction of 2,828 shares valued at $0.
No significant insider buying has been recorded for TERN in the recent period.
No significant insider selling has been recorded for TERN in the recent period.
Based on recent SEC filings, insider sentiment for TERN is bullish with an Insider Alignment Score of 87/100 and a net flow of $76.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Terns Pharmaceuticals, Inc. (TERN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading TERN stock, having executed 104 transactions in the past 90 days. The most active insider is Hongbo Lu (Executive), who has made 7 transactions totaling $19.6M.
Get notified when executives and directors at TERN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | A. Fellows David | Executive | Award | 2,828 | $N/A | $0 | |
| Feb 1, 2026 | B. Kindler Jeffrey | Executive | Award | 1,697 | $N/A | $0 | |
| Feb 1, 2026 | M. Quigley Jill | Executive | Award | 1,697 | $N/A | $0 | |
| Feb 1, 2026 | Azelby Robert | Executive | Award | 1,697 | $N/A | $0 | |
| Feb 1, 2026 | Tripuraneni Radhika | Executive | Award | 1,697 | $N/A | $0 | |
| Feb 1, 2026 | D. Turner Heather | Executive | Award | 1,697 | $N/A | $0 | |
| Jan 14, 2026 | Gengos Andrew | Chief Financial Officer | Award | 137,500 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | Gengos Andrew | Chief Financial Officer | Award | 68,750 | $N/A | $0 | C-Suite |
| Jan 14, 2026 | Kuriakose Emil | Chief Medical Officer | Award | 112,500 | $N/A | $0 | |
| Jan 14, 2026 | Kuriakose Emil | Chief Medical Officer | Award | 56,250 | $N/A | $0 | |
| Nov 4, 2025 | M. Quigley Jill | Executive | Option Exercise | 24,520 | $9.24 | $226.6K | |
| Nov 4, 2025 | M. Quigley Jill | Executive | Sale | 24,520 | $18.00 | $441.4K | |
| Oct 1, 2025 | Kuriakose Emil | Executive | Sale | 944 | $7.85 | $7.4K | |
| Sep 12, 2024 | Lu Hongbo | Executive | Purchase | 190,476 | $10.50 | $2.0M | Large |
| Sep 12, 2024 | Lu Hongbo | Executive | Purchase | 285,714 | $10.50 | $3.0M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 41 | $89.8M | 86.9% |
Sale(S) | 32 | $13.2M | 12.7% |
Exercise(M) | 5 | $338.4K | 0.3% |
Award(A) | 15 | $0 | 0.0% |
Conversion(C) | 11 | $0 | 0.0% |
Insiders at Terns Pharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 24 insiders making 104 transactions totaling $89.8M in purchases versus $13.2M in sales, the net buying activity of $76.6M signals strong executive confidence. Hongbo Lu (Executive) leads the buying activity with $19.6M in transactions across all time.